12/17
08:00 am
ntra
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
Low
Report
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
12/13
09:29 am
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $160.00 to $200.00. They now have an "overweight" rating on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $160.00 to $200.00. They now have an "overweight" rating on the stock.
12/12
08:17 am
ntra
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer [Yahoo! Finance]
Low
Report
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer [Yahoo! Finance]
12/12
08:00 am
ntra
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
Low
Report
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
12/9
08:24 am
ntra
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment [Yahoo! Finance]
Medium
Report
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment [Yahoo! Finance]
12/9
08:00 am
ntra
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
Low
Report
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
12/3
08:23 am
ntra
Strong Volume Growth Lifted Natera (NTRA) in Q3 [Yahoo! Finance]
Low
Report
Strong Volume Growth Lifted Natera (NTRA) in Q3 [Yahoo! Finance]
12/2
08:19 am
ntra
Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology [Yahoo! Finance]
Low
Report
Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology [Yahoo! Finance]
12/2
08:00 am
ntra
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
Medium
Report
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
11/27
09:05 am
ntra
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients [Yahoo! Finance]
Low
Report
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients [Yahoo! Finance]
11/27
09:00 am
ntra
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
Low
Report
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
11/25
08:02 pm
ntra
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium [Yahoo! Finance]
Medium
Report
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium [Yahoo! Finance]
11/25
07:57 pm
ntra
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
Medium
Report
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
11/25
03:51 pm
ntra
Natera Issues Statement on Guardant Health Litigation
Low
Report
Natera Issues Statement on Guardant Health Litigation
11/25
09:06 am
ntra
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year [Yahoo! Finance]
Medium
Report
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year [Yahoo! Finance]
11/25
09:00 am
ntra
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
Medium
Report
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
11/21
05:34 pm
ntra
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM [Yahoo! Finance]
Low
Report
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM [Yahoo! Finance]
11/21
05:31 pm
ntra
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
Low
Report
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
11/18
12:36 pm
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Piper Sandler from $150.00 to $200.00. They now have an "overweight" rating on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Piper Sandler from $150.00 to $200.00. They now have an "overweight" rating on the stock.
11/14
12:07 pm
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Morgan Stanley from $132.00 to $176.00. They now have an "overweight" rating on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Morgan Stanley from $132.00 to $176.00. They now have an "overweight" rating on the stock.
11/14
03:12 am
ntra
Natera, Inc. (NASDAQ: NTRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Natera, Inc. (NASDAQ: NTRA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/13
01:45 pm
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at TD Cowen from $155.00 to $175.00. They now have a "buy" rating on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at TD Cowen from $155.00 to $175.00. They now have a "buy" rating on the stock.
11/13
11:38 am
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Craig Hallum from $121.00 to $157.00. They now have a "buy" rating on the stock.
Medium
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Craig Hallum from $121.00 to $157.00. They now have a "buy" rating on the stock.
11/13
11:28 am
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $135.00 to $160.00. They now have an "overweight" rating on the stock.
Medium
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $135.00 to $160.00. They now have an "overweight" rating on the stock.
11/13
09:34 am
ntra
Global Preterm Birth Diagnostic Test Kit Market Set for Strong Growth, Projected to Reach USD 316.5 Million by 2034: Key Growth Drivers and Trends | Future Market Insights, Inc. [Yahoo! Finance]
Low
Report
Global Preterm Birth Diagnostic Test Kit Market Set for Strong Growth, Projected to Reach USD 316.5 Million by 2034: Key Growth Drivers and Trends | Future Market Insights, Inc. [Yahoo! Finance]